The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

被引:4
|
作者
Jirapinyo, Pichamol [1 ,2 ,5 ]
Thompson, Christopher C. [1 ,2 ]
Garcia-Tsao, Guadalupe [3 ,4 ]
Zucker, Stephen D. [1 ,2 ]
Ryou, Marvin [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Yale Sch Med, Sect Digest Dis, New Haven, CT USA
[4] VA CT Healthcare Syst, Sect Digest Dis, West Haven, CT USA
[5] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA
关键词
LIFE-STYLE; CIRRHOSIS; FIBROSIS; OBESITY;
D O I
10.1055/a-2146-8857
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The goals of therapy for patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease include weight loss and reduction of the portosystemic pressure gradient (PPG) to decrease the risk of hepatic decompensation. Endoscopic gastric plication (EGP) is an effective endoscopic weight loss procedure. This study aimed to assess the effect of EGP on PPG. Methods In this prospective pilot study, patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease underwent endoscopic ultrasoundguided PPGmeasurement prior to and at 6months following EGP. Primary outcomes were the change in PPG and proportion of patients experiencing . 20% reduction in PPG at 6 months. Secondary outcomes included percent total weight loss (TWL) and changes in noninvasive tests of fibrosis. Results 20 patients were included. Baseline median body mass index and liver stiffness measurement were 40.2 kg/ m2 (range 30.1.56.7) and 14.7 kPa (range 8.2.36), respectively. At 6 months, median PPG decreased from 5.4mmHg (range 0.7.19.6) to 1.8mmHg (range 0.4.17.6) (P = 0.002), with 79% (11/14) experiencing . 20% reduction. Patients experienced 12.5% (6.5%.26.1%) TWL (P < 0.001) at 6 months, with 89% (17/19) achieving . 7% and 68% (13/19) achieving . 10% TWL. There were significant improvements in noninvasive tests of fibrosis. Conclusion EGP appeared to be effective at reducing PPG in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. © 2022 Georg Thieme Verlag. All rights reserved.
引用
收藏
页码:125 / 130
页数:6
相关论文
共 50 条
  • [31] Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease
    Piccinni, Rosangela
    Rodrigues, Susana G.
    Montani, Matteo
    Murgia, Giuseppe
    Delgado, Maria G.
    Casu, Stefania
    Stirnimann, Guido
    Semmo, Nasser
    De Gottardi, Andrea
    Dufour, Jean-Francois
    Berzigotti, Annalisa
    LIVER INTERNATIONAL, 2020, 40 (05) : 1151 - 1158
  • [32] Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease
    Zachary H. Henry
    Stephen H. Caldwell
    Curtis K. Argo
    Current Hepatology Reports, 2016, 15 (2) : 117 - 124
  • [33] The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease
    Malik, Raza
    Chang, Michael
    Bhaskar, Killimangalam
    Nasser, Imad
    Curry, Michael
    Schuppan, Detlef
    Byrnes, Valerie
    Afdhal, Nezam
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (04) : 564 - 568
  • [34] The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease
    Gajos, Andrea
    Tapper, Elliot B.
    CLINICAL THERAPEUTICS, 2021, 43 (03) : 518 - 523
  • [35] Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh
    Alam, Shahinul
    Noor-E-Alam, Sheikh Mohammad
    Chowdhury, Ziaur Rahman
    Alam, Mahabubul
    Kabir, Jahangir
    WORLD JOURNAL OF HEPATOLOGY, 2013, 5 (05) : 281 - 287
  • [36] Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh
    Shahinul Alam
    Sheikh Mohammad Noor-E-Alam
    Ziaur Rahman Chowdhury
    Mahabubul Alam
    Jahangir Kabir
    World Journal of Hepatology, 2013, (05) : 281 - 287
  • [37] Hepatocellular carcinoma surveillance in nonalcoholic fatty liver disease patients
    Truong, Emily
    Noureddin, Mazen
    HEPATOMA RESEARCH, 2022, 8
  • [38] Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis
    Salomone, Federico
    Currenti, Walter
    Magri, Giovanni
    Boskoski, Ivo
    Zelber-Sagi, Shira
    Galvano, Fabio
    LIVER INTERNATIONAL, 2021, 41 (09) : 2112 - 2116
  • [39] Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals
    Pons, Monica
    Santos, Begona
    Simon-Talero, Macarena
    Ventura-Cots, Meritxell
    Riveiro-Barciela, Mar
    Esteban, Rafael
    Augustin, Salvador
    Genesca, Joan
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (08): : 619 - 629
  • [40] Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B
    Zhang, Siyu
    Zhang, Xiaoxiao
    Jin, Huiming
    Dou, Yao
    Li, Lu
    Yuan, Xiwei
    Dong, Chen
    Hou, Mengmeng
    Nan, Yue-Min
    Shang, Jia
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (01) : 67 - 75